2025
SJR Q1
JCR Q1 · 6,8
OA
SCIE
Journal detail
Clinical and Experimental Hypertension
- Publisher
- Taylor & Francis Group LLC Philadelphia
- Country
- United States · Northern America
- Type
- journal
- ISSN
-
1064196315256006
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,934
- Quartile Q1
- H-Index 59
- Cites/doc 6,15
- Docs (3y) 195
- Cites (3y) 759
Clarivate
Web of Science · JCR · 2025
- JCR Q Q1
- JIF 6,8
- 5Y JIF 2,8
- JCI 1,16
WoS indexes
- SCIE
Subject classification
Categories (SJR)
WoS categories
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q1 | Q1 | 0,934 | 6,8 | 2,8 | 1,16 | Q1 | 59 |
| 2024 | Q2 | Q2 | 0,729 | 3,5 | 2,2 | 0,83 | Q2 | 57 |
| 2023 | Q3 | Q3 | 0,448 | 1,5 | 1,6 | 0,48 | Q3 | 57 |
| 2022 | Q3 | Q3 | 0,438 | 2,6 | 2,1 | 0,6 | Q2 | 57 |
| 2021 | Q3 | Q4 | 0,481 | 2,1 | 2 | 0,5 | Q3 | 57 |
| 2020 | Q3 | Q4 | 0,555 | 1,7 | 1,8 | 0,53 | Q3 | 57 |
| 2019 | Q2 | Q4 | 0,52 | 1,8 | 1,5 | 0,51 | Q3 | 57 |
| 2018 | — | Q4 | — | 1,5 | 1,3 | 0,45 | Q3 | — |
| 2017 | Q2 | Q4 | 0,507 | 1,4 | 1,2 | 0,44 | Q3 | 57 |
| 2016 | Q3 | Q4 | 0,42 | 1,2 | 1,1 | — | — | 57 |
| 2015 | Q2 | Q4 | 0,475 | 1,3 | 1,2 | — | — | 57 |
| 2014 | Q2 | Q4 | 0,411 | 1,2 | 1,2 | — | — | 57 |
| 2013 | Q2 | Q3 | 0,558 | 1,5 | 1,4 | — | — | 57 |
| 2012 | Q2 | Q3 | 0,468 | 1,3 | 1,3 | — | — | 57 |
| 2011 | Q2 | Q4 | 0,4 | 1,1 | 1,1 | — | — | 57 |
| 2010 | Q2 | Q4 | 0,332 | 1,1 | 1,1 | — | — | 57 |
| 2009 | — | Q3 | — | 1,3 | 1,3 | — | — | — |
| 2008 | — | Q4 | — | 1,1 | 1,1 | — | — | — |
| 2007 | — | Q4 | — | 1 | 1,1 | — | — | — |
| 2006 | — | Q3 | — | 1,1 | — | — | — | — |
| 2005 | — | Q4 | — | 1 | — | — | — | — |
| 2004 | — | Q4 | — | 1 | — | — | — | — |
| 2003 | — | Q4 | — | 0,8 | — | — | — | — |
| 2002 | — | Q3 | — | 0,9 | — | — | — | — |
| 2001 | — | Q3 | — | 1,3 | — | — | — | — |
| 2000 | — | Q3 | — | 1,3 | — | — | — | — |
| 1999 | — | Q3 | — | 1,2 | — | — | — | — |
| 1998 | — | Q3 | — | 1 | — | — | — | — |
| 1997 | — | Q2 | — | 1,2 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | Q1 | 12/100 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q1 | Q1 | 37/356 |
| 2024 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 26/98 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 107/352 |
| 2023 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 67/96 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 265/354 |
| 2022 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 43/68 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 183/278 |
| 2021 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 54/67 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 228/279 |
| 2020 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 57/65 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 235/276 |
| 2019 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 49/65 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 213/271 |
| 2018 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 55/65 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 218/267 |
| 2017 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | Q3 | 52/65 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | Q3 | 220/261 |
| 2016 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 56/63 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 217/257 |
| 2015 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 54/63 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 205/255 |
| 2014 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 53/60 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 197/255 |
| 2013 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 50/65 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 176/256 |
| 2012 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 50/68 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 193/261 |
| 2011 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 56/68 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 205/261 |
| 2010 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 54/68 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 194/252 |
| 2009 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 45/61 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 178/237 |
| 2008 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 48/56 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 174/219 |
| 2007 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 43/54 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 166/205 |
| 2006 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 37/52 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 147/199 |
| 2005 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 42/51 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 156/193 |
| 2004 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 42/51 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 142/187 |
| 2003 | PERIPHERAL VASCULAR DISEASE | SCIE | Q4 | — | 43/52 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q4 | — | 144/185 |
| 2002 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 37/52 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 137/188 |
| 2001 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 30/50 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 101/186 |
| 2000 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 28/45 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 92/181 |
| 1999 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 25/44 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 89/175 |
| 1998 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 21/39 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 95/178 |
| 1997 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 19/38 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | — | 81/157 |